董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Higgins | 男 | Chairman of the Board and Director | 63 | 14.63万美元 | 48.21 | 2026-06-09 |
| Steven Hyman | 男 | Director | 74 | 10.78万美元 | 18.98 | 2026-06-09 |
| Catherine J. Mackey | 女 | Director | 71 | 10.68万美元 | 7.63 | 2026-06-09 |
| Glenn Pierce | 男 | Director | 70 | 10.48万美元 | 32.18 | 2026-06-09 |
| George Scangos | 男 | Director | 78 | 10.38万美元 | 6.71 | 2026-06-09 |
| Grace E. Colon | 女 | Director | 59 | 10.78万美元 | 7.08 | 2026-06-09 |
| Alfred Sandrock | 男 | Chief Executive Officer and Director and President | 68 | 250.84万美元 | 114.51 | 2026-06-09 |
| Jude Onyia | -- | Director | 62 | 9.88万美元 | 7.37 | 2026-06-09 |
| Nancy Vitale | 女 | Director | 55 | 10.88万美元 | 11.30 | 2026-06-09 |
| James Arthur Geraghty | 男 | Director | 72 | 10.73万美元 | 26.64 | 2026-06-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alfred Sandrock | 男 | Chief Executive Officer and Director and President | 68 | 250.84万美元 | 114.51 | 2026-06-09 |
| Robin Swartz | 女 | Principal Financial Officer, Treasurer, Chief Business Officer and Chief Operating Officer | 55 | 145.43万美元 | 未持股 | 2026-06-09 |
| Todd Carter | 男 | Chief Scientific Officer | 56 | 未披露 | 未持股 | 2026-06-09 |
| Gregory Shiferman | 男 | General Counsel and Secretary and Senior Vice President | 41 | 未披露 | 未持股 | 2026-06-09 |
| Amy Quinlan | 女 | Principal Accounting Officer | 51 | 未披露 | 未持股 | 2026-06-09 |
董事简历
中英对照 | 中文 | 英文- Michael Higgins
-
2015年7月以来Michael Higgins担任Genocea Biosciences董事会的一员。2015年1月作为一名常驻企业家Higgins先生加入了Polaris的合作伙伴。加入Polaris 伙伴之前，Higgins先生担任Ironwood Pharmaceuticals公司的首席运营官和首席财务官。NASDAQ：IRWD从2003年到2014年12月。他在Ironwood工作之前，从1997年到2003年Higgins先生在Genzyme公司担任不同的领导职位包括副总裁、企业融资和副总裁、业务发展。在Genzyme期间，他参与多家企业包括细胞疗法、基因治疗、孤儿疾病业务单位。之前，从1992年到1997年Higgins先生担任Procept公司首席财务官。他也任职于 Genocea Biosciences公司Genocea和 。（纳斯达克：GNCA）和Pulmatrix公司董事会。在1986年作为Schering-Plough 公司的销售代表Higgins先生开始他的制药生涯。Higgins获得Cornell大学理学学士学位和，Dartmouth学院Amos Tuck 商学院的工商管理硕士学位。
Michael Higgins was appointed Chairman of the Board in June 2019. He has been a member of the Board of Directors since July 2015 and also served as Voyager Therapeutics, Inc.'s Interim President and Chief Executive Officer from June 2021 to March 2022. Mr. Higgins has served as chairman of the board of directors of Pulmatrix, Inc., a publicly traded biopharmaceutical company, since April 2020, and Nocion Therapeutics, Inc., a privately held biopharmaceutical company, since September 2020. Mr. Higgins has also served as a member of the board of directors of Cyclerion Therapeutics, Inc., a publicly traded biopharmaceutical company, since November 2023; Camp4 Therapeutics Corporation, a publicly traded biopharmaceutical company, since October 2017; Kindex Pharmaceuticals from 2015 to 2021; and Sea Pharmaceuticals, LLC, a privately held pharmaceutical company, since October 2016. Mr. Higgins previously served as a member of the board of directors of Genocea Biosciences Inc., a publicly traded immuno oncology company, from February 2015 to May 2022. Mr. Higgins is a serial entrepreneur who has helped launch and build numerous companies during his career. He served as Entrepreneur in Residence and Advisor at Polaris Partners, an investment company, from 2015 to 2021. From 2003 to 2014 he served as Senior Vice President, Chief Operating Officer at Ironwood Pharmaceuticals Inc, a biopharmaceutical company. Prior to 2003, Mr. Higgins held a variety of senior business positions at Genzyme Corporation, including Vice President of Corporate Finance and Vice President of Business Development. Mr. Higgins earned a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business at Dartmouth College. - 2015年7月以来Michael Higgins担任Genocea Biosciences董事会的一员。2015年1月作为一名常驻企业家Higgins先生加入了Polaris的合作伙伴。加入Polaris 伙伴之前，Higgins先生担任Ironwood Pharmaceuticals公司的首席运营官和首席财务官。NASDAQ：IRWD从2003年到2014年12月。他在Ironwood工作之前，从1997年到2003年Higgins先生在Genzyme公司担任不同的领导职位包括副总裁、企业融资和副总裁、业务发展。在Genzyme期间，他参与多家企业包括细胞疗法、基因治疗、孤儿疾病业务单位。之前，从1992年到1997年Higgins先生担任Procept公司首席财务官。他也任职于 Genocea Biosciences公司Genocea和 。（纳斯达克：GNCA）和Pulmatrix公司董事会。在1986年作为Schering-Plough 公司的销售代表Higgins先生开始他的制药生涯。Higgins获得Cornell大学理学学士学位和，Dartmouth学院Amos Tuck 商学院的工商管理硕士学位。
- Michael Higgins was appointed Chairman of the Board in June 2019. He has been a member of the Board of Directors since July 2015 and also served as Voyager Therapeutics, Inc.'s Interim President and Chief Executive Officer from June 2021 to March 2022. Mr. Higgins has served as chairman of the board of directors of Pulmatrix, Inc., a publicly traded biopharmaceutical company, since April 2020, and Nocion Therapeutics, Inc., a privately held biopharmaceutical company, since September 2020. Mr. Higgins has also served as a member of the board of directors of Cyclerion Therapeutics, Inc., a publicly traded biopharmaceutical company, since November 2023; Camp4 Therapeutics Corporation, a publicly traded biopharmaceutical company, since October 2017; Kindex Pharmaceuticals from 2015 to 2021; and Sea Pharmaceuticals, LLC, a privately held pharmaceutical company, since October 2016. Mr. Higgins previously served as a member of the board of directors of Genocea Biosciences Inc., a publicly traded immuno oncology company, from February 2015 to May 2022. Mr. Higgins is a serial entrepreneur who has helped launch and build numerous companies during his career. He served as Entrepreneur in Residence and Advisor at Polaris Partners, an investment company, from 2015 to 2021. From 2003 to 2014 he served as Senior Vice President, Chief Operating Officer at Ironwood Pharmaceuticals Inc, a biopharmaceutical company. Prior to 2003, Mr. Higgins held a variety of senior business positions at Genzyme Corporation, including Vice President of Corporate Finance and Vice President of Business Development. Mr. Higgins earned a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business at Dartmouth College.
- Steven Hyman
-
Steven Hyman，自2015年9月成为董事会成员。他担任和哈佛大学和麻省理工学院布罗德研究所斯坦利精神病学研究中心（Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT）董事和布罗德研究所核心教师人员（2012年2月起）。Hyman先生自2011年7月起担任哈佛大学（Harvard University）干细胞和再生生物学著名服务教授。2001年12月-2011年6月他担任哈佛大学（Harvard University）教务长、大学首席学术官。1996-2001年他担任美国精神健康研究所（U.S. National Institute of Mental Health）的董事，专注投资神经科学和新兴基因技术。他于2000年被选如医学研究所（Institute of Medicine）并重命名国家医学院（National Academy of Medicine），目前在理事会、健康科学政策董事会工作，并担任神经科学和神经系统紊乱的董事。他是国际神经伦理学协会（International Neuroethics Society）的创立总裁、美洲艺术科学院（American Academy of Arts and Sciences）的研究员、美国科学发展协会（American Association for the Advancement of Science）研究员、美国神经精神药理学会（American College of Neuropsychopharmacology）的研究员和美国精神病学协会（American Psychiatric Association）著名生命研究员。他拥有耶鲁大学（Yale College）学士学位和剑桥大学（University of Cambridge）硕士学位，担任Mellon研究员，也拥有哈佛医学院（Harvard Medical School）硕士学位。
Steven Hyman has been a member of the Board of Directors since September 2015. He has served as founding director of the Program in Brain Health at the Broad Institute of Harvard and MIT and as a Core Faculty Member of the Broad Institute since March 2012. Dr. Hyman has served as a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology since July 2011. He has served as a member of the board of directors of publicly traded biotechnology company Cyclerion Therapeutics, Inc. since July 2022. From December 2001 to June 2011, he served as Provost of Harvard University, the University's chief academic officer. From 1996 to 2001, he served as Director of the U.S. National Institute of Mental Health, where he emphasized investment in neuroscience and emerging genetic technologies. He was elected to the Institute of Medicine in 2000, renamed the National Academy of Medicine, where he completed his second term on the Governing Council from 2012 to 2018, and has chaired the Forum on Neuroscience and Nervous Systems Disorders. He also served on the governing board of the National Research Council, the operating arm of the U.S. National Academies, from 2016 to 2018. He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, former president of the Society for Neuroscience, former president of the American College of Neuropsychopharmacology, and a Distinguished Life Fellow of the American Psychiatric Association. Dr. Hyman has served as Board Chair of the Charles A. Dana Foundation (NY) since April 2018. Dr. Hyman received a B.A. from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow, and an M.D. from Harvard Medical School. - Steven Hyman，自2015年9月成为董事会成员。他担任和哈佛大学和麻省理工学院布罗德研究所斯坦利精神病学研究中心（Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT）董事和布罗德研究所核心教师人员（2012年2月起）。Hyman先生自2011年7月起担任哈佛大学（Harvard University）干细胞和再生生物学著名服务教授。2001年12月-2011年6月他担任哈佛大学（Harvard University）教务长、大学首席学术官。1996-2001年他担任美国精神健康研究所（U.S. National Institute of Mental Health）的董事，专注投资神经科学和新兴基因技术。他于2000年被选如医学研究所（Institute of Medicine）并重命名国家医学院（National Academy of Medicine），目前在理事会、健康科学政策董事会工作，并担任神经科学和神经系统紊乱的董事。他是国际神经伦理学协会（International Neuroethics Society）的创立总裁、美洲艺术科学院（American Academy of Arts and Sciences）的研究员、美国科学发展协会（American Association for the Advancement of Science）研究员、美国神经精神药理学会（American College of Neuropsychopharmacology）的研究员和美国精神病学协会（American Psychiatric Association）著名生命研究员。他拥有耶鲁大学（Yale College）学士学位和剑桥大学（University of Cambridge）硕士学位，担任Mellon研究员，也拥有哈佛医学院（Harvard Medical School）硕士学位。
- Steven Hyman has been a member of the Board of Directors since September 2015. He has served as founding director of the Program in Brain Health at the Broad Institute of Harvard and MIT and as a Core Faculty Member of the Broad Institute since March 2012. Dr. Hyman has served as a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology since July 2011. He has served as a member of the board of directors of publicly traded biotechnology company Cyclerion Therapeutics, Inc. since July 2022. From December 2001 to June 2011, he served as Provost of Harvard University, the University's chief academic officer. From 1996 to 2001, he served as Director of the U.S. National Institute of Mental Health, where he emphasized investment in neuroscience and emerging genetic technologies. He was elected to the Institute of Medicine in 2000, renamed the National Academy of Medicine, where he completed his second term on the Governing Council from 2012 to 2018, and has chaired the Forum on Neuroscience and Nervous Systems Disorders. He also served on the governing board of the National Research Council, the operating arm of the U.S. National Academies, from 2016 to 2018. He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, former president of the Society for Neuroscience, former president of the American College of Neuropsychopharmacology, and a Distinguished Life Fellow of the American Psychiatric Association. Dr. Hyman has served as Board Chair of the Charles A. Dana Foundation (NY) since April 2018. Dr. Hyman received a B.A. from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow, and an M.D. from Harvard Medical School.
- Catherine J. Mackey
-
Catherine J. Mackey，自2015年2月起担任董事，目前是CYPrus Therapeutics, Inc.（私营小分子制药研发公司）的首席执行官，她于2015年2月加入该公司。她也是MindPiece Partners的顾问（有效），她于2011年成立该公司。她此前于2001年至2010年12月间担任Pfizer的全球研发高级副总裁；此前担任Pfizer康涅狄格州研发总部的战略联盟副总裁；更早领导Pfizer的染色体和蛋白质研究。 在加入Pfizer之前，她在DEKALB Genetics Corporation（被Monsanto Company收购）担任渐升职位，包括企业副总裁与研发主管。她目前是Sequenom, Inc. （NASDAQ： SQNM）（2015.6起）， Cour Pharmaceutical Development Company（2014.3起）和Evolve Biosystems, Inc.（2014.6起）的董事；2011年至2013年2月间担任 YM Biosciences Inc. （被Gilead Sciences Inc.收购）的董事；2010年12月至2013年4月间担任Althea Technologies, Inc. （被Ajinomoto Co., Inc.收购）的董事。她于1977年和1983年分别获得了Cornell University的微生物学学士和博士学位。
Catherine J. Mackey has been a member of the Board of Directors since August 2022. Dr. Mackey has served on the board of directors of publicly traded biotechnology company IDEAYA Biosciences, Inc. since April 2022. She previously served as the Chair of the board of directors of Cour Pharmaceuticals Development Co., Inc., a privately held, clinical stage company focused on immunomodulation, from May 2014 to December 2022. She also previously served as a member of the board of directors of publicly traded biotechnology company Avid Bioservices, Inc. from July 2019 to February 2025, when Avid was acquired by GHO Capital Partners LLP and Ampersand Capital Partners; publicly traded biotechnology company Trillium Therapeutics Inc. from June 2021 to November 2021, when Trillium was acquired by Pfizer Inc.; publicly traded biopharmaceutical company Poseida Therapeutics, Inc. from January 2019 to June 2021; and publicly traded biopharmaceutical company GW Pharmaceuticals plc from December 2017 to May 2021, when GW Pharmaceuticals was acquired by Jazz Pharmaceuticals. Dr. Mackey previously served as Senior Vice President, Pfizer Global Research and Development, and Director, La Jolla Laboratories, of Pfizer, Inc. from 2001 to 2010. Dr. Mackey earned her B.S. and Ph.D. in microbiology from Cornell University. - Catherine J. Mackey，自2015年2月起担任董事，目前是CYPrus Therapeutics, Inc.（私营小分子制药研发公司）的首席执行官，她于2015年2月加入该公司。她也是MindPiece Partners的顾问（有效），她于2011年成立该公司。她此前于2001年至2010年12月间担任Pfizer的全球研发高级副总裁；此前担任Pfizer康涅狄格州研发总部的战略联盟副总裁；更早领导Pfizer的染色体和蛋白质研究。 在加入Pfizer之前，她在DEKALB Genetics Corporation（被Monsanto Company收购）担任渐升职位，包括企业副总裁与研发主管。她目前是Sequenom, Inc. （NASDAQ： SQNM）（2015.6起）， Cour Pharmaceutical Development Company（2014.3起）和Evolve Biosystems, Inc.（2014.6起）的董事；2011年至2013年2月间担任 YM Biosciences Inc. （被Gilead Sciences Inc.收购）的董事；2010年12月至2013年4月间担任Althea Technologies, Inc. （被Ajinomoto Co., Inc.收购）的董事。她于1977年和1983年分别获得了Cornell University的微生物学学士和博士学位。
- Catherine J. Mackey has been a member of the Board of Directors since August 2022. Dr. Mackey has served on the board of directors of publicly traded biotechnology company IDEAYA Biosciences, Inc. since April 2022. She previously served as the Chair of the board of directors of Cour Pharmaceuticals Development Co., Inc., a privately held, clinical stage company focused on immunomodulation, from May 2014 to December 2022. She also previously served as a member of the board of directors of publicly traded biotechnology company Avid Bioservices, Inc. from July 2019 to February 2025, when Avid was acquired by GHO Capital Partners LLP and Ampersand Capital Partners; publicly traded biotechnology company Trillium Therapeutics Inc. from June 2021 to November 2021, when Trillium was acquired by Pfizer Inc.; publicly traded biopharmaceutical company Poseida Therapeutics, Inc. from January 2019 to June 2021; and publicly traded biopharmaceutical company GW Pharmaceuticals plc from December 2017 to May 2021, when GW Pharmaceuticals was acquired by Jazz Pharmaceuticals. Dr. Mackey previously served as Senior Vice President, Pfizer Global Research and Development, and Director, La Jolla Laboratories, of Pfizer, Inc. from 2001 to 2010. Dr. Mackey earned her B.S. and Ph.D. in microbiology from Cornell University.
- Glenn Pierce
-
Glenn Pierce，2016年2月以来，他担任公司的董事会成员。他于2016年2月加入Third Rock Ventures公司（风险资本公司），并担任其驻企高管。2014年5月以来，他曾担任生物技术公司的研究和发展项目的独立顾问。他于2014年5月退任Biogen Inc.（生物技术公司），在那里他曾担任多种职务（2009年3月加入Biogen公司以来），包括血液学首席医疗官、全球医疗事务主管，最近领导血液、细胞和基因疗法部门。他拥有血友病和血红蛋白病的整体研发责任，并领导延长半衰期FVIII和修复Fc融合的研究和临床开发，于2014年最终促成多个监管机构的批准。他是150多篇科学论文的联席作者或合著者，并拥有15项以上的专利。他目前任职于the World Federation of Hemophilia WFH and WFHUSA的董事会、国家血友病基金会（NHF）（美国）医学和科学顾问委员会（the National Hemophilia Foundation （NHF） （U.S。） Medical and Scientific Advisory Council）。他持有 Case Western Reserve University（位于克利夫兰）的医学博士学位、免疫学博士学位，并在圣路易斯华盛顿大学（Washington University in St. Louis）进行病理学和血液学研究的研究生培训。
Glenn Pierce has been a member of the Board of Directors since January 2017 and also served as Voyager Therapeutics, Inc.'s Interim Chief Scientific Officer from June 2021 to June 2022 and a consultant from June 2022 to June 2023. Dr. Pierce served as consultant at Ambys Medicines, a biotechnology company, from August 2020 to March 2022, and previously served as Chief Medical Officer of Ambys from August 2018 to August 2020. Since August 2014, Dr. Pierce has served as a consultant to several biotechnology companies. He has served as an Entrepreneur in Residence at Third Rock Ventures, LLC, a life sciences venture capital firm focused on the formation, development and strategy of new companies, since January 2016. He retired from Biogen Idec, Inc., a biotechnology company, in May 2014, where he had worked since March 2009 and most recently served as Senior Vice President leading the Hematology, Cell and Gene Therapies division. Dr. Pierce also served on the Blood Products Advisory Committee at the U.S. Food and Drug Administration and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He has served on the board of directors of the World Federation of Hemophilia since 2015 and as the organization's Vice President, Medical since 2018. Dr. Pierce also served on the board of directors of publicly traded biopharmaceutical company Global Blood Therapeutics, Inc. (acquired by Pfizer, Inc.) from February 2016 to October 2022. Dr. Pierce received a B.A. in Biology, an M.D., and a Ph.D. in immunology, all from Case Western Reserve University in Cleveland, and completed his postgraduate training in pathology and hematology research at Washington University in St. Louis. - Glenn Pierce，2016年2月以来，他担任公司的董事会成员。他于2016年2月加入Third Rock Ventures公司（风险资本公司），并担任其驻企高管。2014年5月以来，他曾担任生物技术公司的研究和发展项目的独立顾问。他于2014年5月退任Biogen Inc.（生物技术公司），在那里他曾担任多种职务（2009年3月加入Biogen公司以来），包括血液学首席医疗官、全球医疗事务主管，最近领导血液、细胞和基因疗法部门。他拥有血友病和血红蛋白病的整体研发责任，并领导延长半衰期FVIII和修复Fc融合的研究和临床开发，于2014年最终促成多个监管机构的批准。他是150多篇科学论文的联席作者或合著者，并拥有15项以上的专利。他目前任职于the World Federation of Hemophilia WFH and WFHUSA的董事会、国家血友病基金会（NHF）（美国）医学和科学顾问委员会（the National Hemophilia Foundation （NHF） （U.S。） Medical and Scientific Advisory Council）。他持有 Case Western Reserve University（位于克利夫兰）的医学博士学位、免疫学博士学位，并在圣路易斯华盛顿大学（Washington University in St. Louis）进行病理学和血液学研究的研究生培训。
- Glenn Pierce has been a member of the Board of Directors since January 2017 and also served as Voyager Therapeutics, Inc.'s Interim Chief Scientific Officer from June 2021 to June 2022 and a consultant from June 2022 to June 2023. Dr. Pierce served as consultant at Ambys Medicines, a biotechnology company, from August 2020 to March 2022, and previously served as Chief Medical Officer of Ambys from August 2018 to August 2020. Since August 2014, Dr. Pierce has served as a consultant to several biotechnology companies. He has served as an Entrepreneur in Residence at Third Rock Ventures, LLC, a life sciences venture capital firm focused on the formation, development and strategy of new companies, since January 2016. He retired from Biogen Idec, Inc., a biotechnology company, in May 2014, where he had worked since March 2009 and most recently served as Senior Vice President leading the Hematology, Cell and Gene Therapies division. Dr. Pierce also served on the Blood Products Advisory Committee at the U.S. Food and Drug Administration and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He has served on the board of directors of the World Federation of Hemophilia since 2015 and as the organization's Vice President, Medical since 2018. Dr. Pierce also served on the board of directors of publicly traded biopharmaceutical company Global Blood Therapeutics, Inc. (acquired by Pfizer, Inc.) from February 2016 to October 2022. Dr. Pierce received a B.A. in Biology, an M.D., and a Ph.D. in immunology, all from Case Western Reserve University in Cleveland, and completed his postgraduate training in pathology and hematology research at Washington University in St. Louis.
- George Scangos
-
George Scangos自2023年5月起担任董事会成员。Scangos博士于2017年1月至2023年4月期间担任Vir Biotechnology公司总裁兼首席执行官。他于2017年1月至2024年5月期间担任Vir Biotechnology, Inc.的董事会成员。2010年7月至2016年12月，Scangos博士担任生物技术公司Biogen Inc.的首席执行官和董事会成员。在渤健期间，Scangos博士被《财富》杂志评为“年度商业人物”，并被《哈佛商业评论》评为2014、2015和2016年各年度“全球表现最佳的CEO”之一。Scangos博士此前于1996年10月至2010年7月担任药物发现和开发公司Exelixis, Inc.的总裁兼首席执行官，并于1996年10月至2020年5月担任其董事会成员。从1987年到1996年，Scangos博士在制药公司拜耳公司担任越来越重要的职务，并在1993年到1996年担任生物技术总裁达到高潮。在加入拜耳之前，Scangos博士是约翰霍普金斯大学的生物学教授。Scangos博士目前还担任安捷伦科技公司的董事会成员，该公司是一家上市的生命科学、诊断和应用化学分析公司，自2014年起担任该公司董事；Octave Bioscience，Inc.是一家开发神经退行性疾病精准医学方法的私营公司，自2017年起担任该公司董事；Rezo Therapeutics，Inc.是一家私营生物技术公司，该公司阐明了涉及多种疾病的网络，他自2021年起担任该公司董事。Scangos博士于2016年担任美国药物研究和制造商主席，并于2010年担任加州医疗保健研究所主席。2006年至2010年，他是全球结核病药物开发联盟的董事会成员。Scangos博士目前担任Life Science Cares湾区分会的董事会成员，该组织致力于利用生物技术行业的资源帮助来自弱势背景的个人。Scangos博士在康奈尔大学获得生物学学士学位，在马萨诸塞大学获得微生物学博士学位。
George Scangos has been a member of the Board of Directors since May 2023. Dr. Scangos served as President and Chief Executive Officer of Vir Biotechnology, Inc. from January 2017 until April 2023. He was a member of the board of directors of Vir Biotechnology, Inc., from January 2017 until May 2024. From July 2010 to December 2016, Dr. Scangos served as Chief Executive Officer and as a member of the board of directors of Biogen Inc., a biotechnology company. While at Biogen, Dr. Scangos was named a "Business Person of the Year" by Fortune Magazine and one of "The Best Performing CEOs in the World" by Harvard Business Review for each of the years 2014, 2015, and 2016. Dr. Scangos previously served as President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company, from October 1996 to July 2010 and as a member of its board of directors from October 1996 to May 2020. From 1987 to 1996, Dr. Scangos served in positions of increasing responsibility at Bayer Corporation, a pharmaceutical company, culminating with his service as President of Biotechnology from 1993 to 1996. Before joining Bayer, Dr. Scangos was a Professor of Biology at Johns Hopkins University. Dr. Scangos also currently serves on the boards of directors of Agilent Technologies, Inc., a publicly traded life sciences, diagnostics and applied chemical analysis company, where he has been a director since 2014; Octave Bioscience, Inc., a privately held company developing precision medicine approaches for neurodegenerative diseases, where he has been a director since 2017; and Rezo Therapeutics, Inc., a privately held biotechnology company elucidating the networks involved in a variety of diseases, where he has been a director since 2021. Dr. Scangos served as Chair of Pharmaceutical Research and Manufacturers of America in 2016, and as the Chair of the California Healthcare Institute in 2010. He was a member of the board of directors of the Global Alliance for TB Drug Development from 2006 until 2010. Dr. Scangos currently serves on the board of directors of the Bay Area chapter of Life Science Cares, an organization devoted to using the resources of the biotechnology industry to help individuals from disadvantaged backgrounds. Dr. Scangos received his B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts. - George Scangos自2023年5月起担任董事会成员。Scangos博士于2017年1月至2023年4月期间担任Vir Biotechnology公司总裁兼首席执行官。他于2017年1月至2024年5月期间担任Vir Biotechnology, Inc.的董事会成员。2010年7月至2016年12月，Scangos博士担任生物技术公司Biogen Inc.的首席执行官和董事会成员。在渤健期间，Scangos博士被《财富》杂志评为“年度商业人物”，并被《哈佛商业评论》评为2014、2015和2016年各年度“全球表现最佳的CEO”之一。Scangos博士此前于1996年10月至2010年7月担任药物发现和开发公司Exelixis, Inc.的总裁兼首席执行官，并于1996年10月至2020年5月担任其董事会成员。从1987年到1996年，Scangos博士在制药公司拜耳公司担任越来越重要的职务，并在1993年到1996年担任生物技术总裁达到高潮。在加入拜耳之前，Scangos博士是约翰霍普金斯大学的生物学教授。Scangos博士目前还担任安捷伦科技公司的董事会成员，该公司是一家上市的生命科学、诊断和应用化学分析公司，自2014年起担任该公司董事；Octave Bioscience，Inc.是一家开发神经退行性疾病精准医学方法的私营公司，自2017年起担任该公司董事；Rezo Therapeutics，Inc.是一家私营生物技术公司，该公司阐明了涉及多种疾病的网络，他自2021年起担任该公司董事。Scangos博士于2016年担任美国药物研究和制造商主席，并于2010年担任加州医疗保健研究所主席。2006年至2010年，他是全球结核病药物开发联盟的董事会成员。Scangos博士目前担任Life Science Cares湾区分会的董事会成员，该组织致力于利用生物技术行业的资源帮助来自弱势背景的个人。Scangos博士在康奈尔大学获得生物学学士学位，在马萨诸塞大学获得微生物学博士学位。
- George Scangos has been a member of the Board of Directors since May 2023. Dr. Scangos served as President and Chief Executive Officer of Vir Biotechnology, Inc. from January 2017 until April 2023. He was a member of the board of directors of Vir Biotechnology, Inc., from January 2017 until May 2024. From July 2010 to December 2016, Dr. Scangos served as Chief Executive Officer and as a member of the board of directors of Biogen Inc., a biotechnology company. While at Biogen, Dr. Scangos was named a "Business Person of the Year" by Fortune Magazine and one of "The Best Performing CEOs in the World" by Harvard Business Review for each of the years 2014, 2015, and 2016. Dr. Scangos previously served as President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company, from October 1996 to July 2010 and as a member of its board of directors from October 1996 to May 2020. From 1987 to 1996, Dr. Scangos served in positions of increasing responsibility at Bayer Corporation, a pharmaceutical company, culminating with his service as President of Biotechnology from 1993 to 1996. Before joining Bayer, Dr. Scangos was a Professor of Biology at Johns Hopkins University. Dr. Scangos also currently serves on the boards of directors of Agilent Technologies, Inc., a publicly traded life sciences, diagnostics and applied chemical analysis company, where he has been a director since 2014; Octave Bioscience, Inc., a privately held company developing precision medicine approaches for neurodegenerative diseases, where he has been a director since 2017; and Rezo Therapeutics, Inc., a privately held biotechnology company elucidating the networks involved in a variety of diseases, where he has been a director since 2021. Dr. Scangos served as Chair of Pharmaceutical Research and Manufacturers of America in 2016, and as the Chair of the California Healthcare Institute in 2010. He was a member of the board of directors of the Global Alliance for TB Drug Development from 2006 until 2010. Dr. Scangos currently serves on the board of directors of the Bay Area chapter of Life Science Cares, an organization devoted to using the resources of the biotechnology industry to help individuals from disadvantaged backgrounds. Dr. Scangos received his B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.
- Grace E. Colon
-
Grace E. Colon自2023年1月起担任董事会成员。自2026年1月以来，她一直担任私人控股的OmniPulse Biosciences的首席执行官、总裁和董事会成员。她曾于2016年11月至2023年12月担任私营诊断公司ProterixBio，Inc.（前身为BioScale，Inc.）的执行主席和董事会成员，并于2015年2月至2016年10月担任ProterixBio的总裁兼首席执行官。Col ó n博士还在风险投资公司New Science Ventures担任过各种职务，包括2014年1月至2016年6月担任合伙人，2016年7月至2019年6月担任高级顾问。在任职New Science Ventures之前，她的经历包括：2010年10月至2012年5月，在上市的生物制药公司Precigen, Inc.（原Intrexon Corporation）担任高级副总裁和工业产品部门的创始总裁；2005年2月至2010年8月，在上市的生物制药公司吉利德科学公司TERM2担任各种职务，担任越来越多的职责，最近担任全球临床运营主管；在上市的基因组学公司（被赛默飞世尔，Inc.收购）的Affymetrix, Inc.，担任企业规划副总裁，2000年8月至2005年1月。2024年3月，Col ó n博士当选为美国医学和生物工程学会（AIMBE）院士。Col ó n博士在麻省理工学院获得化学工程博士学位，在那里她是美国国家科学基金会的研究员，并在宾夕法尼亚大学获得化学工程学士学位，在那里她是本杰明·富兰克林学者。
Grace E. Colon has been a member of the Board of Directors since January 2023. She has been CEO, President and member of the board of directors of privately held OmniPulse Biosciences since January 2026. She previously served as the Executive Chair and a member of the board of directors of ProterixBio, Inc. (formerly Bioscale, Inc.), a privately held diagnostics company, from November 2016 to December 2023, and President and Chief Executive Officer of ProterixBio from February 2015 to October 2016. Dr. Colón also served in various capacities with New Science Ventures, a venture capital firm, including as Partner from January 2014 to June 2016 and Senior Advisor from July 2016 through June 2019. Prior to her time at New Science Ventures, her experiences include roles such as Senior Vice President and the founding President of the Industrial Products Division at Precigen, Inc. (formerly Intrexon Corporation), a publicly traded biopharmaceutical company, from October 2010 to May 2012; in various capacities of increasing responsibility at Gilead Sciences, Inc., a publicly traded biopharmaceutical company, from February 2005 to August 2010, most recently as head of Global Clinical Operations; and as Vice President of Corporate Planning at Affymetrix, Inc., a publicly traded genomics company (acquired by Thermo Fisher Scientific, Inc.), from August 2000 to January 2005.In March 2024, Dr. Colón was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was a National Science Foundation Fellow, and earned a B.S. in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar. - Grace E. Colon自2023年1月起担任董事会成员。自2026年1月以来，她一直担任私人控股的OmniPulse Biosciences的首席执行官、总裁和董事会成员。她曾于2016年11月至2023年12月担任私营诊断公司ProterixBio，Inc.（前身为BioScale，Inc.）的执行主席和董事会成员，并于2015年2月至2016年10月担任ProterixBio的总裁兼首席执行官。Col ó n博士还在风险投资公司New Science Ventures担任过各种职务，包括2014年1月至2016年6月担任合伙人，2016年7月至2019年6月担任高级顾问。在任职New Science Ventures之前，她的经历包括：2010年10月至2012年5月，在上市的生物制药公司Precigen, Inc.（原Intrexon Corporation）担任高级副总裁和工业产品部门的创始总裁；2005年2月至2010年8月，在上市的生物制药公司吉利德科学公司TERM2担任各种职务，担任越来越多的职责，最近担任全球临床运营主管；在上市的基因组学公司（被赛默飞世尔，Inc.收购）的Affymetrix, Inc.，担任企业规划副总裁，2000年8月至2005年1月。2024年3月，Col ó n博士当选为美国医学和生物工程学会（AIMBE）院士。Col ó n博士在麻省理工学院获得化学工程博士学位，在那里她是美国国家科学基金会的研究员，并在宾夕法尼亚大学获得化学工程学士学位，在那里她是本杰明·富兰克林学者。
- Grace E. Colon has been a member of the Board of Directors since January 2023. She has been CEO, President and member of the board of directors of privately held OmniPulse Biosciences since January 2026. She previously served as the Executive Chair and a member of the board of directors of ProterixBio, Inc. (formerly Bioscale, Inc.), a privately held diagnostics company, from November 2016 to December 2023, and President and Chief Executive Officer of ProterixBio from February 2015 to October 2016. Dr. Colón also served in various capacities with New Science Ventures, a venture capital firm, including as Partner from January 2014 to June 2016 and Senior Advisor from July 2016 through June 2019. Prior to her time at New Science Ventures, her experiences include roles such as Senior Vice President and the founding President of the Industrial Products Division at Precigen, Inc. (formerly Intrexon Corporation), a publicly traded biopharmaceutical company, from October 2010 to May 2012; in various capacities of increasing responsibility at Gilead Sciences, Inc., a publicly traded biopharmaceutical company, from February 2005 to August 2010, most recently as head of Global Clinical Operations; and as Vice President of Corporate Planning at Affymetrix, Inc., a publicly traded genomics company (acquired by Thermo Fisher Scientific, Inc.), from August 2000 to January 2005.In March 2024, Dr. Colón was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was a National Science Foundation Fellow, and earned a B.S. in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.
- Alfred Sandrock
-
Alfred Sandrock自2022年2月起担任董事会成员，并自2022年3月起担任Voyager Therapeutics, Inc.总裁兼首席执行官。从1998年2月到2021年12月，Sandrock博士在Biogen Inc.担任越来越重要的职务，最终于2019年10月至2021年12月担任研发执行副总裁。Sandrock博士还在2012年至2020年期间担任过多个首席医疗官职务，包括2015年10月至2020年1月担任执行副总裁、渤健首席医疗官，并于2013年6月至2021年12月担任渤健执行委员会成员。Sandrock博士在职期间曾担任渤健其他高级管理职务，包括集团高级副总裁兼首席医疗官、首席医疗官兼发展科学高级副总裁、神经病学研发高级副总裁以及神经病学临床开发副总裁。Sandrock博士自2022年2月起担任私营生物技术公司Transition Bio，Inc.的董事会成员，自2022年2月起担任Neurimmune，Inc.的董事会成员，自2025年2月起担任Neutargeton Therapeutics的董事会成员。Sandrock博士于2015年9月至2020年5月期间担任上市生物技术公司Neurocrine Biosciences, Inc.（“Neurocrine”）的董事会成员，并于2017年5月至2020年2月期间担任私营生物技术公司Praxis Precision Medicines，Inc.的董事会成员，于2017年4月至2020年10月期间担任Disarm Therapeutics，Inc.的董事会成员，于2022年3月至2024年9月期间担任Atalanta Therapeutics，Inc.的董事会成员，于2022年2月至2026年期间担任Verge Genomics Inc.的董事会成员。Sandrock博士获得了斯坦福大学人类生物学学士学位、哈佛医学院医学博士学位和哈佛大学神经生物学博士学位。
Alfred Sandrock has been a member of the Board of Directors since February 2022 and has served as Voyager Therapeutics, Inc.'s President and Chief Executive Officer since March 2022. From February 1998 to December 2021, Dr. Sandrock served in positions of increasing responsibility at Biogen Inc., culminating in his service as Executive Vice President, Research and Development from October 2019 to December 2021. Dr. Sandrock also served in various Chief Medical Officer roles from 2012 to 2020, including as Executive Vice President, Chief Medical Officer for Biogen from October 2015 to January 2020, and served on Biogen's Executive Committee from June 2013 to December 2021. Dr. Sandrock held other senior executive positions at Biogen during his tenure, including Group Senior Vice President and Chief Medical Officer, Chief Medical Officer and Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock has served on the boards of directors of privately held biotechnology companies Transition Bio, Inc. since February 2022, Neurimmune, Inc. since February 2022, and Neutargeton Therapeutics since February 2025. Dr. Sandrock served on the boards of directors of publicly traded biotechnology company Neurocrine Biosciences, Inc. ("Neurocrine") from September 2015 to May 2020 and privately held biotechnology companies Praxis Precision Medicines, Inc. from May 2017 to February 2020, Disarm Therapeutics, Inc. from April 2017 to October 2020, Atalanta Therapeutics, Inc. from March 2022 to September 2024, and Verge Genomics Inc. from February 2022 to March 2026. Dr. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. - Alfred Sandrock自2022年2月起担任董事会成员，并自2022年3月起担任Voyager Therapeutics, Inc.总裁兼首席执行官。从1998年2月到2021年12月，Sandrock博士在Biogen Inc.担任越来越重要的职务，最终于2019年10月至2021年12月担任研发执行副总裁。Sandrock博士还在2012年至2020年期间担任过多个首席医疗官职务，包括2015年10月至2020年1月担任执行副总裁、渤健首席医疗官，并于2013年6月至2021年12月担任渤健执行委员会成员。Sandrock博士在职期间曾担任渤健其他高级管理职务，包括集团高级副总裁兼首席医疗官、首席医疗官兼发展科学高级副总裁、神经病学研发高级副总裁以及神经病学临床开发副总裁。Sandrock博士自2022年2月起担任私营生物技术公司Transition Bio，Inc.的董事会成员，自2022年2月起担任Neurimmune，Inc.的董事会成员，自2025年2月起担任Neutargeton Therapeutics的董事会成员。Sandrock博士于2015年9月至2020年5月期间担任上市生物技术公司Neurocrine Biosciences, Inc.（“Neurocrine”）的董事会成员，并于2017年5月至2020年2月期间担任私营生物技术公司Praxis Precision Medicines，Inc.的董事会成员，于2017年4月至2020年10月期间担任Disarm Therapeutics，Inc.的董事会成员，于2022年3月至2024年9月期间担任Atalanta Therapeutics，Inc.的董事会成员，于2022年2月至2026年期间担任Verge Genomics Inc.的董事会成员。Sandrock博士获得了斯坦福大学人类生物学学士学位、哈佛医学院医学博士学位和哈佛大学神经生物学博士学位。
- Alfred Sandrock has been a member of the Board of Directors since February 2022 and has served as Voyager Therapeutics, Inc.'s President and Chief Executive Officer since March 2022. From February 1998 to December 2021, Dr. Sandrock served in positions of increasing responsibility at Biogen Inc., culminating in his service as Executive Vice President, Research and Development from October 2019 to December 2021. Dr. Sandrock also served in various Chief Medical Officer roles from 2012 to 2020, including as Executive Vice President, Chief Medical Officer for Biogen from October 2015 to January 2020, and served on Biogen's Executive Committee from June 2013 to December 2021. Dr. Sandrock held other senior executive positions at Biogen during his tenure, including Group Senior Vice President and Chief Medical Officer, Chief Medical Officer and Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock has served on the boards of directors of privately held biotechnology companies Transition Bio, Inc. since February 2022, Neurimmune, Inc. since February 2022, and Neutargeton Therapeutics since February 2025. Dr. Sandrock served on the boards of directors of publicly traded biotechnology company Neurocrine Biosciences, Inc. ("Neurocrine") from September 2015 to May 2020 and privately held biotechnology companies Praxis Precision Medicines, Inc. from May 2017 to February 2020, Disarm Therapeutics, Inc. from April 2017 to October 2020, Atalanta Therapeutics, Inc. from March 2022 to September 2024, and Verge Genomics Inc. from February 2022 to March 2026. Dr. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University.
- Jude Onyia
-
Jude Onyia自2023年2月起担任董事会成员。Onyia博士自2021年11月起担任Neurocrine的首席科学官，领导药物发现和非临床开发团队。Onyia博士此前曾于2021年6月至2021年11月担任基因治疗平台公司Capsida Biotherapeutics，Inc.的首席科学官。从1995年1月到2021年6月，Onyia博士在制药公司礼来公司担任过各种职责不断增加的角色，包括从2014年9月到2021年6月担任生物技术发现研究副总裁。Onyia博士拥有纽约州立大学（SUNY）环境科学与林业学院的森林生物学学士学位，以及锡拉丘兹SUNY健康科学中心的细胞和分子生物学博士学位。
Jude Onyia has been a member of the Board of Directors since February 2023. Dr. Onyia has served as the Chief Scientific Officer of Neurocrine since November 2021 and leads the drug discovery and non clinical development teams. Dr. Onyia previously served as the Chief Scientific Officer of Capsida Biotherapeutics, Inc., a gene therapy platform company, from June 2021 to November 2021. From January 1995 to June 2021, Dr. Onyia served in various roles of increasing responsibility with Eli Lilly and Company, a pharmaceutical company, including as Vice President of Biotechnology Discovery Research from September 2014 to June 2021. Dr. Onyia holds a B.S. in forest biology from the State University of New York (SUNY) College of Environmental Science and Forestry, and a Ph.D. in cell and molecular biology from the SUNY Health Science Center at Syracuse. - Jude Onyia自2023年2月起担任董事会成员。Onyia博士自2021年11月起担任Neurocrine的首席科学官，领导药物发现和非临床开发团队。Onyia博士此前曾于2021年6月至2021年11月担任基因治疗平台公司Capsida Biotherapeutics，Inc.的首席科学官。从1995年1月到2021年6月，Onyia博士在制药公司礼来公司担任过各种职责不断增加的角色，包括从2014年9月到2021年6月担任生物技术发现研究副总裁。Onyia博士拥有纽约州立大学（SUNY）环境科学与林业学院的森林生物学学士学位，以及锡拉丘兹SUNY健康科学中心的细胞和分子生物学博士学位。
- Jude Onyia has been a member of the Board of Directors since February 2023. Dr. Onyia has served as the Chief Scientific Officer of Neurocrine since November 2021 and leads the drug discovery and non clinical development teams. Dr. Onyia previously served as the Chief Scientific Officer of Capsida Biotherapeutics, Inc., a gene therapy platform company, from June 2021 to November 2021. From January 1995 to June 2021, Dr. Onyia served in various roles of increasing responsibility with Eli Lilly and Company, a pharmaceutical company, including as Vice President of Biotechnology Discovery Research from September 2014 to June 2021. Dr. Onyia holds a B.S. in forest biology from the State University of New York (SUNY) College of Environmental Science and Forestry, and a Ph.D. in cell and molecular biology from the SUNY Health Science Center at Syracuse.
- Nancy Vitale
-
Nancy Vitale自2020年9月起担任董事会成员。Vitale女士自2022年1月起担任Omada Health，Inc.的首席人事官。自2019年7月起，她还担任精品人力资源咨询公司Partners for Wellbeing，LLC的联合创始人，并于2019年7月至2022年1月担任管理合伙人。此前，Vitale女士曾于2006年9月至2019年7月在生物技术公司基因泰克担任多个人力资源领导职务，她是罗氏集团的成员，包括首席人力资源官和高级副总裁。在加入基因泰克公司之前，Vitale女士于2004年4月至2006年8月在消费品公司宝洁担任吉列北美商业运营部门人力资源主管，并于2001年4月至2004年4月在健康服务公司信诺保险集团公司担任人力资源副总裁。Vitale女士于2017年1月至2021年7月担任Make a Wish Foundation的董事会成员。Vitale女士获得了密歇根大学的学士学位和埃默里大学Goizueta商学院的工商管理硕士学位。
Nancy Vitale has been a member of the Board of Directors since September 2020. Ms. Vitale has served as Chief People Officer at Omada Health, Inc., since January 2022. She has also served as a Co Founder at Partners for Wellbeing, LLC, a boutique human resources consulting firm, since July 2019, and served as Managing Partner from July 2019 January 2022. Previously, Ms. Vitale served in various human resources leadership roles at biotechnology company Genentech, Inc., a member of the Roche Group, from September 2006 to July 2019, including Chief Human Resources Officer and Senior Vice President. Prior to her time at Genentech, Ms. Vitale served as Head of Human Resources, Gillette North America Commercial Operations at Procter & Gamble, a consumer goods company, from April 2004 to August 2006 and as Vice President of Human Resources at Cigna Corporation, a health service company, from April 2001 to April 2004. Ms. Vitale served on the Board of Directors for the Make A Wish Foundation from January 2017 to July 2021. Ms. Vitale received a B.B.A. from the University of Michigan and an M.B.A. from the Goizueta Business School at Emory University. - Nancy Vitale自2020年9月起担任董事会成员。Vitale女士自2022年1月起担任Omada Health，Inc.的首席人事官。自2019年7月起，她还担任精品人力资源咨询公司Partners for Wellbeing，LLC的联合创始人，并于2019年7月至2022年1月担任管理合伙人。此前，Vitale女士曾于2006年9月至2019年7月在生物技术公司基因泰克担任多个人力资源领导职务，她是罗氏集团的成员，包括首席人力资源官和高级副总裁。在加入基因泰克公司之前，Vitale女士于2004年4月至2006年8月在消费品公司宝洁担任吉列北美商业运营部门人力资源主管，并于2001年4月至2004年4月在健康服务公司信诺保险集团公司担任人力资源副总裁。Vitale女士于2017年1月至2021年7月担任Make a Wish Foundation的董事会成员。Vitale女士获得了密歇根大学的学士学位和埃默里大学Goizueta商学院的工商管理硕士学位。
- Nancy Vitale has been a member of the Board of Directors since September 2020. Ms. Vitale has served as Chief People Officer at Omada Health, Inc., since January 2022. She has also served as a Co Founder at Partners for Wellbeing, LLC, a boutique human resources consulting firm, since July 2019, and served as Managing Partner from July 2019 January 2022. Previously, Ms. Vitale served in various human resources leadership roles at biotechnology company Genentech, Inc., a member of the Roche Group, from September 2006 to July 2019, including Chief Human Resources Officer and Senior Vice President. Prior to her time at Genentech, Ms. Vitale served as Head of Human Resources, Gillette North America Commercial Operations at Procter & Gamble, a consumer goods company, from April 2004 to August 2006 and as Vice President of Human Resources at Cigna Corporation, a health service company, from April 2001 to April 2004. Ms. Vitale served on the Board of Directors for the Make A Wish Foundation from January 2017 to July 2021. Ms. Vitale received a B.B.A. from the University of Michigan and an M.B.A. from the Goizueta Business School at Emory University.
- James Arthur Geraghty
-
James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。于2018年07月18日获委任为北海康成制药有限公司提名及企业管治委员会委员。于2022年02月16日获委任为北海康成制药有限公司审核委员会委员。
James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc. - James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。于2018年07月18日获委任为北海康成制药有限公司提名及企业管治委员会委员。于2022年02月16日获委任为北海康成制药有限公司审核委员会委员。
- James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc.
高管简历
中英对照 | 中文 | 英文- Alfred Sandrock
Alfred Sandrock自2022年2月起担任董事会成员，并自2022年3月起担任Voyager Therapeutics, Inc.总裁兼首席执行官。从1998年2月到2021年12月，Sandrock博士在Biogen Inc.担任越来越重要的职务，最终于2019年10月至2021年12月担任研发执行副总裁。Sandrock博士还在2012年至2020年期间担任过多个首席医疗官职务，包括2015年10月至2020年1月担任执行副总裁、渤健首席医疗官，并于2013年6月至2021年12月担任渤健执行委员会成员。Sandrock博士在职期间曾担任渤健其他高级管理职务，包括集团高级副总裁兼首席医疗官、首席医疗官兼发展科学高级副总裁、神经病学研发高级副总裁以及神经病学临床开发副总裁。Sandrock博士自2022年2月起担任私营生物技术公司Transition Bio，Inc.的董事会成员，自2022年2月起担任Neurimmune，Inc.的董事会成员，自2025年2月起担任Neutargeton Therapeutics的董事会成员。Sandrock博士于2015年9月至2020年5月期间担任上市生物技术公司Neurocrine Biosciences, Inc.（“Neurocrine”）的董事会成员，并于2017年5月至2020年2月期间担任私营生物技术公司Praxis Precision Medicines，Inc.的董事会成员，于2017年4月至2020年10月期间担任Disarm Therapeutics，Inc.的董事会成员，于2022年3月至2024年9月期间担任Atalanta Therapeutics，Inc.的董事会成员，于2022年2月至2026年期间担任Verge Genomics Inc.的董事会成员。Sandrock博士获得了斯坦福大学人类生物学学士学位、哈佛医学院医学博士学位和哈佛大学神经生物学博士学位。
Alfred Sandrock has been a member of the Board of Directors since February 2022 and has served as Voyager Therapeutics, Inc.'s President and Chief Executive Officer since March 2022. From February 1998 to December 2021, Dr. Sandrock served in positions of increasing responsibility at Biogen Inc., culminating in his service as Executive Vice President, Research and Development from October 2019 to December 2021. Dr. Sandrock also served in various Chief Medical Officer roles from 2012 to 2020, including as Executive Vice President, Chief Medical Officer for Biogen from October 2015 to January 2020, and served on Biogen's Executive Committee from June 2013 to December 2021. Dr. Sandrock held other senior executive positions at Biogen during his tenure, including Group Senior Vice President and Chief Medical Officer, Chief Medical Officer and Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock has served on the boards of directors of privately held biotechnology companies Transition Bio, Inc. since February 2022, Neurimmune, Inc. since February 2022, and Neutargeton Therapeutics since February 2025. Dr. Sandrock served on the boards of directors of publicly traded biotechnology company Neurocrine Biosciences, Inc. ("Neurocrine") from September 2015 to May 2020 and privately held biotechnology companies Praxis Precision Medicines, Inc. from May 2017 to February 2020, Disarm Therapeutics, Inc. from April 2017 to October 2020, Atalanta Therapeutics, Inc. from March 2022 to September 2024, and Verge Genomics Inc. from February 2022 to March 2026. Dr. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University.- Alfred Sandrock自2022年2月起担任董事会成员，并自2022年3月起担任Voyager Therapeutics, Inc.总裁兼首席执行官。从1998年2月到2021年12月，Sandrock博士在Biogen Inc.担任越来越重要的职务，最终于2019年10月至2021年12月担任研发执行副总裁。Sandrock博士还在2012年至2020年期间担任过多个首席医疗官职务，包括2015年10月至2020年1月担任执行副总裁、渤健首席医疗官，并于2013年6月至2021年12月担任渤健执行委员会成员。Sandrock博士在职期间曾担任渤健其他高级管理职务，包括集团高级副总裁兼首席医疗官、首席医疗官兼发展科学高级副总裁、神经病学研发高级副总裁以及神经病学临床开发副总裁。Sandrock博士自2022年2月起担任私营生物技术公司Transition Bio，Inc.的董事会成员，自2022年2月起担任Neurimmune，Inc.的董事会成员，自2025年2月起担任Neutargeton Therapeutics的董事会成员。Sandrock博士于2015年9月至2020年5月期间担任上市生物技术公司Neurocrine Biosciences, Inc.（“Neurocrine”）的董事会成员，并于2017年5月至2020年2月期间担任私营生物技术公司Praxis Precision Medicines，Inc.的董事会成员，于2017年4月至2020年10月期间担任Disarm Therapeutics，Inc.的董事会成员，于2022年3月至2024年9月期间担任Atalanta Therapeutics，Inc.的董事会成员，于2022年2月至2026年期间担任Verge Genomics Inc.的董事会成员。Sandrock博士获得了斯坦福大学人类生物学学士学位、哈佛医学院医学博士学位和哈佛大学神经生物学博士学位。
- Alfred Sandrock has been a member of the Board of Directors since February 2022 and has served as Voyager Therapeutics, Inc.'s President and Chief Executive Officer since March 2022. From February 1998 to December 2021, Dr. Sandrock served in positions of increasing responsibility at Biogen Inc., culminating in his service as Executive Vice President, Research and Development from October 2019 to December 2021. Dr. Sandrock also served in various Chief Medical Officer roles from 2012 to 2020, including as Executive Vice President, Chief Medical Officer for Biogen from October 2015 to January 2020, and served on Biogen's Executive Committee from June 2013 to December 2021. Dr. Sandrock held other senior executive positions at Biogen during his tenure, including Group Senior Vice President and Chief Medical Officer, Chief Medical Officer and Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock has served on the boards of directors of privately held biotechnology companies Transition Bio, Inc. since February 2022, Neurimmune, Inc. since February 2022, and Neutargeton Therapeutics since February 2025. Dr. Sandrock served on the boards of directors of publicly traded biotechnology company Neurocrine Biosciences, Inc. ("Neurocrine") from September 2015 to May 2020 and privately held biotechnology companies Praxis Precision Medicines, Inc. from May 2017 to February 2020, Disarm Therapeutics, Inc. from April 2017 to October 2020, Atalanta Therapeutics, Inc. from March 2022 to September 2024, and Verge Genomics Inc. from February 2022 to March 2026. Dr. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University.
- Robin Swartz
Robin Swartz自2024年11月起担任公司首席运营官和首席商务官，此前曾于2022年2月至2024年11月担任公司首席运营官，于2024年4月至2024年7月担任公司首席财务官和首席会计官，于2021年9月至2022年2月担任公司业务运营高级副总裁，于2021年1月至2021年8月担任公司投资组合管理和患者参与高级副总裁。在加入公司之前，Swartz女士于1995年开始在健赞和赛诺菲 Genzyme担任越来越重要的职务，最终于2018年1月至2020年6月在赛诺菲 Genzyme担任罕见病患者和产品服务高级副总裁，并于2015年6月至2017年12月担任高级副总裁兼全球和美国业务运营主管。她此前在赛诺菲健赞担任的职务包括参谋长至执行副总裁、赛诺菲健赞负责人以及财务高级总监。Swartz女士在赛诺菲 Genzyme的财务部门担任了超过十年的职责增加，重点关注财务运营、内部审计以及财务规划和分析。斯沃茨女士在肯扬学院获得政治学和政府学士学位。
Robin Swartz has served as the Company's Chief Operating Officer and Chief Business Officer since November 2024, and previously served as the Company's Chief Operating Officer from February 2022 to November 2024, the Company's Principal Financial Officer and Principal Accounting Officer from April 2024 to July 2024, the Company's Senior Vice President, Business Operations from September 2021 to February 2022 and the Company's Senior Vice President, Portfolio Management and Patient Engagement from January 2021 to August 2021. Prior to joining the Company, Ms. Swartz served in positions of increasing responsibility beginning in 1995 at Genzyme Corporation and Sanofi Genzyme, culminating in her service at Sanofi Genzyme as Senior Vice President, Patient and Product Services for Rare Diseases from January 2018 to June 2020 and as Senior Vice President, Head of Global and US Business Operations from June 2015 to December 2017. Her previous roles at Sanofi Genzyme included Chief of Staff to the Executive Vice President, Head of Sanofi Genzyme and Senior Director, Finance. Ms. Swartz spent over ten years serving in roles of increasing responsibility in the Finance department at Sanofi Genzyme, with a focus on finance operations, internal auditing, and financial planning and analysis. Ms. Swartz received a B.A. in political science and government from Kenyon College.- Robin Swartz自2024年11月起担任公司首席运营官和首席商务官，此前曾于2022年2月至2024年11月担任公司首席运营官，于2024年4月至2024年7月担任公司首席财务官和首席会计官，于2021年9月至2022年2月担任公司业务运营高级副总裁，于2021年1月至2021年8月担任公司投资组合管理和患者参与高级副总裁。在加入公司之前，Swartz女士于1995年开始在健赞和赛诺菲 Genzyme担任越来越重要的职务，最终于2018年1月至2020年6月在赛诺菲 Genzyme担任罕见病患者和产品服务高级副总裁，并于2015年6月至2017年12月担任高级副总裁兼全球和美国业务运营主管。她此前在赛诺菲健赞担任的职务包括参谋长至执行副总裁、赛诺菲健赞负责人以及财务高级总监。Swartz女士在赛诺菲 Genzyme的财务部门担任了超过十年的职责增加，重点关注财务运营、内部审计以及财务规划和分析。斯沃茨女士在肯扬学院获得政治学和政府学士学位。
- Robin Swartz has served as the Company's Chief Operating Officer and Chief Business Officer since November 2024, and previously served as the Company's Chief Operating Officer from February 2022 to November 2024, the Company's Principal Financial Officer and Principal Accounting Officer from April 2024 to July 2024, the Company's Senior Vice President, Business Operations from September 2021 to February 2022 and the Company's Senior Vice President, Portfolio Management and Patient Engagement from January 2021 to August 2021. Prior to joining the Company, Ms. Swartz served in positions of increasing responsibility beginning in 1995 at Genzyme Corporation and Sanofi Genzyme, culminating in her service at Sanofi Genzyme as Senior Vice President, Patient and Product Services for Rare Diseases from January 2018 to June 2020 and as Senior Vice President, Head of Global and US Business Operations from June 2015 to December 2017. Her previous roles at Sanofi Genzyme included Chief of Staff to the Executive Vice President, Head of Sanofi Genzyme and Senior Director, Finance. Ms. Swartz spent over ten years serving in roles of increasing responsibility in the Finance department at Sanofi Genzyme, with a focus on finance operations, internal auditing, and financial planning and analysis. Ms. Swartz received a B.A. in political science and government from Kenyon College.
- Todd Carter
Todd Carter自2022年9月起担任Voyager Therapeutics, Inc.的首席科学官。此前曾于2022年3月至2022年9月担任Voyager Therapeutics, Inc.的研究高级副总裁，2018年11月至2022年3月担任Voyager Therapeutics, Inc.的研究副总裁，并于2016年6月至2018年11月担任Voyager Therapeutics, Inc.的神经科学高级总监。在2016年加入Voyager Therapeutics公司之前，Carter博士曾担任麻省理工学院和哈佛大学布罗德研究所所长办公室的高级科学顾问。此前，他在BrainCells Inc.担任生物学高级总监，负责监督研究工作。Carter博士获得了得克萨斯农工大学的遗传学学士学位和哥伦比亚大学的遗传学博士学位，他在索尔克生物医学研究所完成了博士后培训。
Todd Carter has served as Voyager Therapeutics, Inc.'s Chief Scientific Officer since September 2022. He previously served as Voyager Therapeutics, Inc.'s Senior Vice President of Research from March 2022 to September 2022, Voyager Therapeutics, Inc.'s Vice President of Research from November 2018 to March 2022, and as Voyager Therapeutics, Inc.'s Senior Director, Neuroscience from June 2016 to November 2018. Prior to joining Voyager Therapeutics, Inc. in 2016, Dr. Carter served as the Senior Science Advisor to the Office of the Director of the Broad Institute of MIT and Harvard. Previously, he oversaw research at BrainCells Inc. as Senior Director of Biology. Dr. Carter received a B.A. in genetics from Texas A&M University and a Ph.D. in genetics from Columbia University, and he completed his postdoctoral training at the Salk Institute for Biomedical Research.- Todd Carter自2022年9月起担任Voyager Therapeutics, Inc.的首席科学官。此前曾于2022年3月至2022年9月担任Voyager Therapeutics, Inc.的研究高级副总裁，2018年11月至2022年3月担任Voyager Therapeutics, Inc.的研究副总裁，并于2016年6月至2018年11月担任Voyager Therapeutics, Inc.的神经科学高级总监。在2016年加入Voyager Therapeutics公司之前，Carter博士曾担任麻省理工学院和哈佛大学布罗德研究所所长办公室的高级科学顾问。此前，他在BrainCells Inc.担任生物学高级总监，负责监督研究工作。Carter博士获得了得克萨斯农工大学的遗传学学士学位和哥伦比亚大学的遗传学博士学位，他在索尔克生物医学研究所完成了博士后培训。
- Todd Carter has served as Voyager Therapeutics, Inc.'s Chief Scientific Officer since September 2022. He previously served as Voyager Therapeutics, Inc.'s Senior Vice President of Research from March 2022 to September 2022, Voyager Therapeutics, Inc.'s Vice President of Research from November 2018 to March 2022, and as Voyager Therapeutics, Inc.'s Senior Director, Neuroscience from June 2016 to November 2018. Prior to joining Voyager Therapeutics, Inc. in 2016, Dr. Carter served as the Senior Science Advisor to the Office of the Director of the Broad Institute of MIT and Harvard. Previously, he oversaw research at BrainCells Inc. as Senior Director of Biology. Dr. Carter received a B.A. in genetics from Texas A&M University and a Ph.D. in genetics from Columbia University, and he completed his postdoctoral training at the Salk Institute for Biomedical Research.
- Gregory Shiferman
Gregory Shiferman自2026年1月起担任Voyager Therapeutics, Inc.的高级副总裁、总法律顾问和秘书。在加入Voyager Therapeutics, Inc.之前，Shiferman先生曾在Sage Therapeutics, Inc.担任越来越重要的职务，担任法律和项目领导职务，最终于2024年11月至2025年8月担任高级副总裁、总法律顾问和秘书，于2022年2月至2024年10月担任副总裁、项目负责人，并于2019年7月至2022年2月担任副总裁、公司法律顾问。在加入Sage Therapeutics之前，他于2017年6月至2018年3月担任Takeda Oncology的高级企业顾问，并于2015年7月至2017年6月担任阿瑞雅德的企业顾问。Shiferman先生于2011年10月至2015年7月期间担任Skadden，Arps，Slate，Meagher & Flom LLP & Affiliates律师事务所的协理，并于2010年8月至2011年9月期间担任罗德岛高等法院分配给尊敬的Michael A. Silverstein法官的法律文员。Shiferman先生拥有波士顿大学的学士学位和Benjamin N. Cardozo法学院的法学博士学位。
Gregory Shiferman has served as Voyager Therapeutics, Inc.'s Senior Vice President, General Counsel and Secretary since January 2026. Prior to joining Voyager Therapeutics, Inc., Mr. Shiferman served in positions of increasing responsibility at Sage Therapeutics, Inc., in both legal and program leadership roles, culminating in his service as Senior Vice President, General Counsel and Secretary from November 2024 to August 2025, Vice President, Program Lead from February 2022 to October 2024, and Vice President, Corporate Counsel from July 2019 to February 2022. Prior to joining Sage Therapeutics, he served as Senior Corporate Counsel at Takeda Oncology from June 2017 to March 2018 and as Corporate Counsel at ARIAD Pharmaceuticals from July 2015 to June 2017. Mr. Shiferman was an Associate at the law firm of Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates from October 2011 to July 2015, and a Law Clerk assigned to the Honorable Michael A. Silverstein at the Rhode Island Superior Court from August 2010 to September 2011. Mr. Shiferman holds a B.A. from Boston University and a J.D. from the Benjamin N. Cardozo School of Law.- Gregory Shiferman自2026年1月起担任Voyager Therapeutics, Inc.的高级副总裁、总法律顾问和秘书。在加入Voyager Therapeutics, Inc.之前，Shiferman先生曾在Sage Therapeutics, Inc.担任越来越重要的职务，担任法律和项目领导职务，最终于2024年11月至2025年8月担任高级副总裁、总法律顾问和秘书，于2022年2月至2024年10月担任副总裁、项目负责人，并于2019年7月至2022年2月担任副总裁、公司法律顾问。在加入Sage Therapeutics之前，他于2017年6月至2018年3月担任Takeda Oncology的高级企业顾问，并于2015年7月至2017年6月担任阿瑞雅德的企业顾问。Shiferman先生于2011年10月至2015年7月期间担任Skadden，Arps，Slate，Meagher & Flom LLP & Affiliates律师事务所的协理，并于2010年8月至2011年9月期间担任罗德岛高等法院分配给尊敬的Michael A. Silverstein法官的法律文员。Shiferman先生拥有波士顿大学的学士学位和Benjamin N. Cardozo法学院的法学博士学位。
- Gregory Shiferman has served as Voyager Therapeutics, Inc.'s Senior Vice President, General Counsel and Secretary since January 2026. Prior to joining Voyager Therapeutics, Inc., Mr. Shiferman served in positions of increasing responsibility at Sage Therapeutics, Inc., in both legal and program leadership roles, culminating in his service as Senior Vice President, General Counsel and Secretary from November 2024 to August 2025, Vice President, Program Lead from February 2022 to October 2024, and Vice President, Corporate Counsel from July 2019 to February 2022. Prior to joining Sage Therapeutics, he served as Senior Corporate Counsel at Takeda Oncology from June 2017 to March 2018 and as Corporate Counsel at ARIAD Pharmaceuticals from July 2015 to June 2017. Mr. Shiferman was an Associate at the law firm of Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates from October 2011 to July 2015, and a Law Clerk assigned to the Honorable Michael A. Silverstein at the Rhode Island Superior Court from August 2010 to September 2011. Mr. Shiferman holds a B.A. from Boston University and a J.D. from the Benjamin N. Cardozo School of Law.
- Amy Quinlan
Amy Quinlan自2025年1月起担任公司财务副总裁。在加入公司之前，Quinlan女士于2020年9月至2025年1月在Vor Biopharma公司担任财务副总裁。在加入Vor Biopharma之前，Quinlan女士曾在Tetraphase Pharmaceuticals, Inc.担任越来越多的职责，包括2008年至2020年1月担任高级董事、财务总监，并于2020年1月至2020年9月担任副总裁、财务总监。Quinlan女士获得了布莱恩特大学的财务会计学士学位。
Amy Quinlan has served as the Company's Vice President of Finance since January 2025. Prior to joining the Company, Ms. Quinlan served as Vice President of Finance at Vor Biopharma Inc. from September 2020 to January 2025. Before Vor Biopharma, Ms. Quinlan served in roles of increasing responsibility at Tetraphase Pharmaceuticals, Inc., including as Senior Director, Controller from 2008 to January 2020 and as Vice President, Controller from January 2020 to September 2020. Ms. Quinlan received a B.S. in Financial Accounting from Bryant University.- Amy Quinlan自2025年1月起担任公司财务副总裁。在加入公司之前，Quinlan女士于2020年9月至2025年1月在Vor Biopharma公司担任财务副总裁。在加入Vor Biopharma之前，Quinlan女士曾在Tetraphase Pharmaceuticals, Inc.担任越来越多的职责，包括2008年至2020年1月担任高级董事、财务总监，并于2020年1月至2020年9月担任副总裁、财务总监。Quinlan女士获得了布莱恩特大学的财务会计学士学位。
- Amy Quinlan has served as the Company's Vice President of Finance since January 2025. Prior to joining the Company, Ms. Quinlan served as Vice President of Finance at Vor Biopharma Inc. from September 2020 to January 2025. Before Vor Biopharma, Ms. Quinlan served in roles of increasing responsibility at Tetraphase Pharmaceuticals, Inc., including as Senior Director, Controller from 2008 to January 2020 and as Vice President, Controller from January 2020 to September 2020. Ms. Quinlan received a B.S. in Financial Accounting from Bryant University.